1016/j
epidermidis bacteremia (Figure 1), despite appropriately targeted antimicrobials with maintained MIC to both vancomycin and linezolid, his therapy was changed to intravenous daptomycin 8 mg/kg every 48 h with synergistic ceftaroline 300 mg three times daily, dose-adjusted based on his estimated creatinine The patient was initially treated with vancomycin combined with gentamicin, but vancomycin was switched to daptomycin (8 mg/kg) because of acute renal injury, and linezolid (600 mg every 12 h) was used to treat the MRSA in the lungs
We conducted a multicentre prospective cohort study to compare linezolid and daptomycin (≥ In multivariate logistic regression analysis, there was a significantly higher odds of clinical failure for patients treated with daptomycin as compared with linezolid (adjusted odds ratio 2
It is only available as an intravenous formulation and is FDA approved for complicated skin and skin structure infections and Staphylococcus aureus bacteremia, at doses ranging from 4 to 6 mg/kg/day
Linezolid and daptomycin are the primary treatment options for VRE-BSI, but optimal treatment is unclear
The patient was discharged in stable condition to a rehabilitation facility to complete a 6-week course of daptomycin for MRSA bacteremia, cervical osteomyelitis, and wound infection in combination with a 3-week course of linezolid and rifampin for meningitis related to shunt infection
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study
Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies
7% vs 0
4755)
A report of the treatment of vancomycin-resistant enterococcal (VRE) bacteremia showed that 30-day mortality of daptomycin was higher than that of linezolid
For linezolid MIC determination, the MIC median (MIC 50), MIC for 90% growth (MIC 90), and range for linezolid were 1
The antimicrobial agents available for treatment of enterococcal infection are reviewed here, followed by treatment approaches for clinical syndromes caused by enterococci
Studies comparing daptomycin to linezolid treatment for VRE bacteremia, published until August 2012, were identified from the MEDLINE Ceftaroline, Dalbavancin, Daptomycin, Linezolid, Oritavancin, Quinupristin-dalfopristin, Tedizolid, Telavancin, and Tigecycline Recommendations for Use seen among tigecycline-treated patients with ventilator-associated pneumonia and bacteremia at baseline (9/18 [50
172 The total direct costs of linezolid, daptomycin, and vancomycin were USD $18,057, $20,698, and $23,671, respectively
g
Therefore, there is an urgent need for effective and innovative antibacterial drugs to treat patients with infections caused by While treatment options for VRE bacteremia are limited, linezolid is currently FDA-approved for VRE infection
8% of the linezolid group versus 46
We attempted a systematic review Abstract
There have been several studies comparing linezolid and daptomycin for VRE bacteremia and endocarditis, with mixed results
Out of 98 patients with VRE bacteraemia, 68 were treated with linezolid and 30 with daptomycin
Linezolid 600mg IV/PO q12h
68 (25495779, 19900794, 16195255, 17852941) Currently, vancomycin remains preferred for MRSA bacteremia
It is indicated for gram-positive infections and approved for the treatment of bacterial pneumonia, skin and skin structure infections, and vancomycin-resistant enterococcal (VRE) infections, including infections complicated by bacteremia
Comparison of daptomycin and linezolid for VRE bacteraemia
3% [2/24] vs 14
Daptomycin and linezolid are primary treatment options although definitive clinical data to assess
Skin and Soft-Tissue Infections in Community-Associated MRSA
2 of the 4 most recent and robust meta-analyses showed improved survival with linezolid compared to daptomycin (the other 2
An important
Fowler, Jr
Although limited data is available, the current meta-analysis shows that linezolid treatment for VRE bacteremia was associated with a lower mortality than
Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose
However, daptomycin is considered to be at least as effective as vancomycin in treating MRSA bacteremia, and a high dose of daptomycin is recommended in
Linezolid (LZD) affords superior tissue penetration to VCM or DAP and has been successfully used as salvage therapy for persistent MRSA bacteremia, indicating
Linezolid, which has bacteriostatic activity, is approved for the treatment of vancomycin-resistant enterococci
Thirteen days after switching to daptomycin and linezolid, the MRSA bacteremia test results were negative
The present article reviews the pharmacokinetic properties of vancomycin, linezolid, tigecycline and daptomycin
033)
The objective of this study was to evaluate the treatment of MRSA bacteremia with daptomycin, linezolid and vancomycin
This text and table is intended for use as a study tool to assist people learning pharmacology of agents used for vancomycin-resistant enterococci (VRE) infections in the acute care setting
Moreover, the infection-related mortality and the in-hospital mortality were higher in the daptomycin group compared to the linezolid group
5 µg/mL, 2 µg/mL, and 0
Enterococcal species can cause a variety of infections, including urinary tract infections, bacteremia, endocarditis, and meningitis
Limited therapeutic options exist for the treatment of vancomycin-resistant Enterococcus (VRE) bacteremia; the most commonly used are daptomycin and linezolid
001), higher median APACHE II score (16 vs 14, P =
172 The total direct costs of linezolid, daptomycin, and vancomycin were USD $18,057, $20,698, and $23,671, respectively
3
However, because of its bacteriostatic nature, there are concerns about using linezolid for the treatment of VRE bacteremia
3%, increased lengths of stay of 11
Ceftobiprole was noninferior to daptomycin with respect to overall treatment success in patients with complicated S
ABSTRACT Limited therapeutic options exist for the treatment of vancomycin-resistant Enterococcus (VRE) bacteremia; the most commonly
Treatment options for vancomycin-resistant enterococci (VRE) bloodstream infection are limited